Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 1, 2007

Court Found Synthon IP Infringed Norvasc Patents

  • A court ruled against Synthon IP in a patent infringement case related to Pfizer’s hypertension drug, Norvasc. The Federal District Court in the Eastern District of Virginia found that Synthon IP obtained, by inequitable conduct, two U.S. patents covering a process and an intermediate compound used to make the active ingredient in the medication.

    Pfizer intends to seek attorneys' fees from Synthon.

    Pfizer reported the court ruled that Synthon had knowingly failed to disclose to the U.S. Patent Office Pfizer publications and other information it had in its possession that described the process Synthon sought to patent.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »